NEWS
Alizé Pharma closes a funding round of 3,3 Million euros
Alizé Pharma, a group of companies developing drugs for the treatment of metabolic diseases and cancer, announces today that it has completed a funding round of 3.3 million euros. The funds will allow to take AZP-531, its UAG (UnAcylated Ghrelin) analog, into Phase I clinical trials.
Alizé Pharma will carry out the first (Phase I) clinical trial of AZP-531 in healthy volunteers in 2013, which will be followed by Phase Ib and Phase II trials in patients with type 2 diabetes as well as in patients suffering from the Prader Willi syndrome.
